14-16 November 2018



ichorlogo_cmy copy_lrg

Ichor is dedicated to the clinical application and commercialization of its TriGrid® electroporation technology for the delivery of nucleic acid based biologics to treat numerous disease indications including cancer, chronic viral infections, HIV, and multiple biodefense agents.  Ichor has established R&D collaborations and licensing agreements with partners such as Pfizer, Janssen, Scancell, Genexine, Washington University, IAVI and others.  Ichor continues to seek strategic partnerships to provide our enabling technology to collaborators interested in expanding their product pipeline.